Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $26.7 million.

  • Janux Therapeutics' Non-Current Assets fell 7.03% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.7 million, marking a year-over-year decrease of 7.03%. This contributed to the annual value of $27.9 million for FY2024, which is 10.64% down from last year.
  • Per Janux Therapeutics' latest filing, its Non-Current Assets stood at $26.7 million for Q3 2025, which was up 0.08% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Non-Current Assets registered a high of $32.2 million during Q2 2023, and its lowest value of $215,000 during Q2 2021.
  • For the 3-year period, Janux Therapeutics' Non-Current Assets averaged around $29.4 million, with its median value being $29.5 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 12,597.67% in 2022, then declined by 10.64% in 2024.
  • Over the past 5 years, Janux Therapeutics' Non-Current Assets (Quarterly) stood at $2.8 million in 2021, then soared by 1,025.53% to $31.6 million in 2022, then fell by 1.28% to $31.2 million in 2023, then fell by 10.64% to $27.9 million in 2024, then decreased by 7.03% to $26.7 million in 2025.
  • Its Non-Current Assets stands at $26.7 million for Q3 2025, versus $26.7 million for Q2 2025 and $27.4 million for Q1 2025.